Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

German Government Joins Superbug Fight With €40m CARB-X Investment

Executive Summary

Germany’s Ministry of Education and Research has pledged €40m over four years to the antibacterial accelerator CARB-X, part of an overall €500m the country has committed to fighting superbugs in the next decade.

You may also be interested in...



Vedanta Receives Cash Injection To Proceed With Microbiome-Derived Pipeline

Vedanta’s latest financing allows it to push three of its microbiome-based drug candidates further into the clinic, with big name partners such as BMS and Janssen onboard.

Four Early-Stage Antibacterial Drugs To Watch: Highlights From IDWeek

Promising drugs from Tetraphase, ContraFect, Spero and Entasis get a platform at the Infectious Diseases Society of America’s IDWeek.

REPAIR Is Trying To Fix The Antibiotic Gap Left By Industry

As large biopharmaceutical companies continue to exit antibacterial R&D, investments by Novo Holding’s REPAIR Impact Fund and grants from CARB-X can push forward novel therapies for drug-resistant microbial infections.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC124905

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel